Shuo Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuo Yang has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Rong Li
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, China
9 shared publications - Jie Qiao
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
5 shared publications - Rui Yang
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, China
5 shared publications - Wei Guo
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
3 shared publications - Xiaoying Zheng
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
3 shared publications - Zi Yang
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1) , 1112
The impact of anogenital distance on vaginal and anal microbiota in women with polycystic ovary syndrome and its implications for pregnancy outcomes
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, yet its etiopathogenesis remains poorly understood. There is ongoing debate regarding the diagnostic criteria for PCOS, with various clinical biomarkers proposed but none achieving widespread acceptance. This study investigated anogenital distance (AGD) and its relationship with microbiota in women with PCOS. Significant differences in AGD were observed between PCOS patients and a control group, with notable variations in anal microbiota. Specifically, relative abundances of Faecalibacterium and Gardnerella differed significantly between the two groups. The clinical pregnancy rate per embryo transfer was higher in the control group, indicating potentially poorer reproductive outcomes in the PCOS group. AGD metrics (AGD_ AC and AGD_ AF ) were identified as predictors of clinical pregnancy outcomes, with optimal cutoff values of 87.2 mm and 26.7 mm, respectively. These results provide initial evidence that AGD and microbiota may play roles in reproductive health in PCOS, warranting further research to validate these associations and explore their implications for treatment and prevention strategies in affected individuals.
- 21 July 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1) , 1112
Open AccessThe impact of anogenital distance on vaginal and anal microbiota in women with polycystic ovary syndrome and its implications for pregnancy outcomes
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, yet its etiopathogenesis remains poorly understood. There is ongoing debate regarding the diagnostic criteria for PCOS, with various clinical biomarkers proposed but none achieving widespread acceptance. This study investigated anogenital distance (AGD) and its relationship with microbiota in women with PCOS. Significant differences in AGD were observed between PCOS patients and a control group, with notable variations in anal microbiota. Specifically, relative abundances of Faecalibacterium and Gardnerella differed significantly between the two groups. The clinical pregnancy rate per embryo transfer was higher in the control group, indicating potentially poorer reproductive outcomes in the PCOS group. AGD metrics (AGD_ AC and AGD_ AF ) were identified as predictors of clinical pregnancy outcomes, with optimal cutoff values of 87.2 mm and 26.7 mm, respectively. These results provide initial evidence that AGD and microbiota may play roles in reproductive health in PCOS, warranting further research to validate these associations and explore their implications for treatment and prevention strategies in affected individuals.
- Open Access
- 14 July 2026
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1)
Impact of autoimmune thyroiditis on IVF outcomes in patients with polycystic ovary syndrome and chronic endometritis
To investigate the impact of autoimmune thyroiditis (AIT) on IVF/ICSI outcomes in patients with polycystic ovary syndrome (PCOS) and chronic endometritis (
- 14 July 2026
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1)
Open AccessImpact of autoimmune thyroiditis on IVF outcomes in patients with polycystic ovary syndrome and chronic endometritis
To investigate the impact of autoimmune thyroiditis (AIT) on IVF/ICSI outcomes in patients with polycystic ovary syndrome (PCOS) and chronic endometritis (
- Open Access
- 14 April 2026
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1)
Cumulative live birth after unstimulated in vitro maturation versus conventional in vitro fertilization (IVF) in women with polycystic ovary syndrome: a 36-month retrospective matched cohort study
Polycystic ovary syndrome (PCOS) is characterized by heterogeneous ovarian responsiveness and a heightened risk of ovarian hyperstimulation syndrome (OHSS)
- 14 April 2026
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1)
Open AccessCumulative live birth after unstimulated in vitro maturation versus conventional in vitro fertilization (IVF) in women with polycystic ovary syndrome: a 36-month retrospective matched cohort study
Polycystic ovary syndrome (PCOS) is characterized by heterogeneous ovarian responsiveness and a heightened risk of ovarian hyperstimulation syndrome (OHSS)
- Top Cited Papers
- 21 January 2026
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (4) , 1271-1283
Endometrial microbiota-dimethylglycine-Treg cell axis affects endometrial receptivity in recurrent implantation failure
Recurrent implantation failure (RIF) poses a substantial challenge in assisted reproductive technologies, causing serious psychological burden and economic pressure to patients with infertility. However, the pathogenesis of RIF remains unclear; therefore, in-depth research on RIF is crucial for guiding clinical treatment. Recent studies have indicated that reproductive tract microbiota imbalance is closely related to RIF, making it a new and promising research direction to explore. The present study shows that during the secretory phase, alpha diversity of the endometrial microbiota (EnM) significantly differed (P=0.022) between the RIF and control groups. Moreover, beta diversity analysis found significant differences in both the EnM and uterine lavage fluid microbiota (UfM) (both PHoxa-10 and Lif and reducing embryonic implantation sites. Further exploration of the mechanism revealed that this transplantation decreased the proportion of uterine regulatory T (Treg) cells and the expression of DMG. Additionally, DMG supplementation is expected to mitigate the reduction in Treg and the impairment of endometrial receptivity caused by endometrial tissue microbiota disorders. Therefore, alterations in EnM in patients with RIF may alter endometrial metabolites, decrease Treg-cell proportions, affect endometrial receptivity, and ultimately induce recurrent implantation failure.
- 21 January 2026
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (4) , 1271-1283
Top Cited PapersEndometrial microbiota-dimethylglycine-Treg cell axis affects endometrial receptivity in recurrent implantation failure
Recurrent implantation failure (RIF) poses a substantial challenge in assisted reproductive technologies, causing serious psychological burden and economic pressure to patients with infertility. However, the pathogenesis of RIF remains unclear; therefore, in-depth research on RIF is crucial for guiding clinical treatment. Recent studies have indicated that reproductive tract microbiota imbalance is closely related to RIF, making it a new and promising research direction to explore. The present study shows that during the secretory phase, alpha diversity of the endometrial microbiota (EnM) significantly differed (P=0.022) between the RIF and control groups. Moreover, beta diversity analysis found significant differences in both the EnM and uterine lavage fluid microbiota (UfM) (both PHoxa-10 and Lif and reducing embryonic implantation sites. Further exploration of the mechanism revealed that this transplantation decreased the proportion of uterine regulatory T (Treg) cells and the expression of DMG. Additionally, DMG supplementation is expected to mitigate the reduction in Treg and the impairment of endometrial receptivity caused by endometrial tissue microbiota disorders. Therefore, alterations in EnM in patients with RIF may alter endometrial metabolites, decrease Treg-cell proportions, affect endometrial receptivity, and ultimately induce recurrent implantation failure.
- Open Access
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Nutrition
- Vol. 1 (1) , .100004-1-.100004-16
From testosterone to 11-oxygenated androgens: Integrating endocrine biology, nutrition, and systemic health across the lifespan
Androgens, historically regarded as male sex hormones, are increasingly recognized as central regulators of multisystem physiology across the lifespan in both sexes. Beyond reproductive functions, classical androgens together with emerging 11-oxygenated androgens participate in the regulation of metabolic homeostasis, immune balance, cardiovascular function, musculoskeletal integrity, neurocognitive processes, and systemic aging. Advances in steroidomics, liquid chromatography–tandem mass spectrometry (LC-MS/MS), and androgen receptor biology are reshaping androgen research from a reproduction-centered perspective toward an integrated endocrine framework linking physiology, disease, nutrition, and precision medicine.This review synthesizes current understanding of androgen biosynthesis, metabolism, and receptor signaling, and summarizes their roles in reproductive disorders such as polycystic ovary syndrome, congenital adrenal hyperplasia, and late-onset hypogonadism, as well as prostate disease, metabolic and cardiovascular disorders, bone and muscle health, dermatologic conditions, and neuropsychiatric function. Therapeutic approaches-including hormone replacement therapy, selective androgen receptor modulators, enzyme-targeted interventions, and structured safety monitoring-are also discussed.An emerging frontier is the integration of nutrition and gut microbiota into androgen regulation. Micronutrients such as zinc, magnesium, and vitamin D, together with balanced macronutrient intake, anti-inflammatory dietary patterns, and probiotics, influence steroidogenesis, inflammation, insulin resistance, and androgen receptor signaling, forming a potential “nutrition–microbiota–androgen axis”.Meanwhile, LC-MS/MS-based multi-androgen profiling and early integration with AI approaches-such as ovarian-endocrine-age modeling exemplified by OvaRePred-may enable individualized interpretation and predictive analytics. Collectively, the convergence of advanced analytics, nutrition science, and AI-driven modeling is redefining androgen medicine and enabling more precise diagnosis and personalized endocrine health management.
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Nutrition
- Vol. 1 (1) , .100004-1-.100004-16
Open AccessFrom testosterone to 11-oxygenated androgens: Integrating endocrine biology, nutrition, and systemic health across the lifespan
Androgens, historically regarded as male sex hormones, are increasingly recognized as central regulators of multisystem physiology across the lifespan in both sexes. Beyond reproductive functions, classical androgens together with emerging 11-oxygenated androgens participate in the regulation of metabolic homeostasis, immune balance, cardiovascular function, musculoskeletal integrity, neurocognitive processes, and systemic aging. Advances in steroidomics, liquid chromatography–tandem mass spectrometry (LC-MS/MS), and androgen receptor biology are reshaping androgen research from a reproduction-centered perspective toward an integrated endocrine framework linking physiology, disease, nutrition, and precision medicine.This review synthesizes current understanding of androgen biosynthesis, metabolism, and receptor signaling, and summarizes their roles in reproductive disorders such as polycystic ovary syndrome, congenital adrenal hyperplasia, and late-onset hypogonadism, as well as prostate disease, metabolic and cardiovascular disorders, bone and muscle health, dermatologic conditions, and neuropsychiatric function. Therapeutic approaches-including hormone replacement therapy, selective androgen receptor modulators, enzyme-targeted interventions, and structured safety monitoring-are also discussed.An emerging frontier is the integration of nutrition and gut microbiota into androgen regulation. Micronutrients such as zinc, magnesium, and vitamin D, together with balanced macronutrient intake, anti-inflammatory dietary patterns, and probiotics, influence steroidogenesis, inflammation, insulin resistance, and androgen receptor signaling, forming a potential “nutrition–microbiota–androgen axis”.Meanwhile, LC-MS/MS-based multi-androgen profiling and early integration with AI approaches-such as ovarian-endocrine-age modeling exemplified by OvaRePred-may enable individualized interpretation and predictive analytics. Collectively, the convergence of advanced analytics, nutrition science, and AI-driven modeling is redefining androgen medicine and enabling more precise diagnosis and personalized endocrine health management.
- Open Access
- 15 May 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1338683
The late-follicular-phase progesterone to retrieved oocytes ratio in normal ovarian responders treated with an antagonist protocol can be used as an index for selecting an embryo transfer strategy and predicting the success rate: a retrospective large-scale study
Objective: To determine whether the late-follicular-phase progesterone to retrieved oocytes (P/O) ratio during in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) impacts pregnancy outcomes.Design: 12,874 cycles were retrospectively categorized into four groups according to the P/O ratio percentile, with divisions at the 25th, 50th and 75th percentiles.Results: The clinical pregnancy and live birth rates of fresh cycle embryos in Group D were significantly lower than those in the other three groups (45.1% and 39.0%, 43.2% and 37.2%, 39.6% and 33.5%, 33.4% and 28.2% in Group A, B, C, D, respectively; both P < 0.008). Multivariate logistic regression analysis revealed a significant negative correlation between the P/O ratio and live birth, particularly when the P/O ratio was ≥0.22 (OR = 0.862, 95% CI [0.774–0.959], P = 0.006).Conclusions: The P/O ratio has certain predictive value for IVF/ICSI pregnancy outcomes and can be used for decision-making decision regarding fresh embryo transfer.
- 15 May 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1338683
Open AccessThe late-follicular-phase progesterone to retrieved oocytes ratio in normal ovarian responders treated with an antagonist protocol can be used as an index for selecting an embryo transfer strategy and predicting the success rate: a retrospective large-scale study
Objective: To determine whether the late-follicular-phase progesterone to retrieved oocytes (P/O) ratio during in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) impacts pregnancy outcomes.Design: 12,874 cycles were retrospectively categorized into four groups according to the P/O ratio percentile, with divisions at the 25th, 50th and 75th percentiles.Results: The clinical pregnancy and live birth rates of fresh cycle embryos in Group D were significantly lower than those in the other three groups (45.1% and 39.0%, 43.2% and 37.2%, 39.6% and 33.5%, 33.4% and 28.2% in Group A, B, C, D, respectively; both P < 0.008). Multivariate logistic regression analysis revealed a significant negative correlation between the P/O ratio and live birth, particularly when the P/O ratio was ≥0.22 (OR = 0.862, 95% CI [0.774–0.959], P = 0.006).Conclusions: The P/O ratio has certain predictive value for IVF/ICSI pregnancy outcomes and can be used for decision-making decision regarding fresh embryo transfer.
- Open Access
- 26 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6210
Clinical Features of Severe Ovarian Hyperstimulation Syndrome with Hydrothorax
Problem: Does the presence of hydrothorax suggest that severe ovarian hyperstimulation syndrome (OHSS) is associated with more severe conditions and worse pregnancy outcomes? Method of study: The clinical data for 868 hospital patients with severe OHSS following IVF-ET at Peking University Third Hospital between 1 January 2016 and 21 July 2021 were retrospectively analysed. The patients were divided into two groups, the ascites alone group (n = 417) and the ascites combined with hydrothorax group (n = 451), to investigate the clinical features and pregnancy outcomes of patients with severe ovarian hyperstimulation syndrome (OHSS) combined with hydrothorax plus ascites. Results: The clinical data for 868 hospital patients with severe OHSS following IVF-ET were included. A total of 51.96% of patients with severe OHSS had hydrothorax plus ascites, mainly bilateral and moderate hydrothorax. Most cases with hydrothorax could be monitored and observed, and only 2.66% of the cases required thoracentesis and pleural drainage. Clinically, the time to visit due to worsening symptoms was longer; the hospital stay was shorter; and the OHSS-related laboratory tests, such as white blood cells (WBC), haematocrit (HCT), and ovarian diameter, were less severe in the ascites combined with hydrothorax group than in the ascites alone group. For live-birth outcomes of IVF-ET, the presence and the volume of hydrothorax were not independent risk factors, while the late onset of OHSS (odds ratio [OR]: 0.857 95% confidence interval [CI]: 0.795, 0.925) and a history of foetal reduction (OR: 13.796 95% CI: 1.808, 105.288) were independent protective factors for live birth. Conclusions: Patients with severe OHSS combined with hydrothorax plus ascites have less severe clinical manifestations and laboratory tests than those with ascites alone. The presence and the volume of hydrothorax are unrelated to live-birth outcomes following in vitro fertilization and embryo transfer (IVF-ET).
- 26 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6210
Open AccessClinical Features of Severe Ovarian Hyperstimulation Syndrome with Hydrothorax
Problem: Does the presence of hydrothorax suggest that severe ovarian hyperstimulation syndrome (OHSS) is associated with more severe conditions and worse pregnancy outcomes? Method of study: The clinical data for 868 hospital patients with severe OHSS following IVF-ET at Peking University Third Hospital between 1 January 2016 and 21 July 2021 were retrospectively analysed. The patients were divided into two groups, the ascites alone group (n = 417) and the ascites combined with hydrothorax group (n = 451), to investigate the clinical features and pregnancy outcomes of patients with severe ovarian hyperstimulation syndrome (OHSS) combined with hydrothorax plus ascites. Results: The clinical data for 868 hospital patients with severe OHSS following IVF-ET were included. A total of 51.96% of patients with severe OHSS had hydrothorax plus ascites, mainly bilateral and moderate hydrothorax. Most cases with hydrothorax could be monitored and observed, and only 2.66% of the cases required thoracentesis and pleural drainage. Clinically, the time to visit due to worsening symptoms was longer; the hospital stay was shorter; and the OHSS-related laboratory tests, such as white blood cells (WBC), haematocrit (HCT), and ovarian diameter, were less severe in the ascites combined with hydrothorax group than in the ascites alone group. For live-birth outcomes of IVF-ET, the presence and the volume of hydrothorax were not independent risk factors, while the late onset of OHSS (odds ratio [OR]: 0.857 95% confidence interval [CI]: 0.795, 0.925) and a history of foetal reduction (OR: 13.796 95% CI: 1.808, 105.288) were independent protective factors for live birth. Conclusions: Patients with severe OHSS combined with hydrothorax plus ascites have less severe clinical manifestations and laboratory tests than those with ascites alone. The presence and the volume of hydrothorax are unrelated to live-birth outcomes following in vitro fertilization and embryo transfer (IVF-ET).
- Open Access
- 4 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5761
Outcomes of the Next In Vitro Fertilization Cycle in Women with Polycystic Ovary Syndrome after a Failed In Vitro Maturation Attempt
Background: In vitro maturation (IVM) is indicated in women with polycystic ovary syndrome (PCOS) who have a very good ovarian response during in vitro fertilization (IVF) and are therefore at high risk of ovarian hyperstimulation syndrome (OHSS). According to the latest practice committee document, IVM could be a major advance in assisted reproductive technology (ART) procedures (reduced cost and simplified treatment); nevertheless, retrospective studies of IVM versus IVF still demonstrate lower chances of a live birth with IVM. Could IVM prove to be an optimal first-line treatment approach? And limited information is available concerning the success of the subsequent IVF cycle after the failure of an IVM cycle. Does IVM treatment adversely affect the subsequent IVF cycle, and is this worth considering before performing the IVF cycle for women with PCOS? Methods: This prospective nested case–control study at the Peking University Reproductive Medicine center in China was performed between March 2018 and September 2020. Women aged 20–38 years with PCOS and infertility and who were scheduled for their first IVF attempt were eligible. A total of 351 women were randomly allocated to receive one cycle of unstimulated natural IVM (n = 175) or one cycle of standard IVF with a flexible GnRH antagonist protocol followed by hCG as an ovulation trigger (n = 176). This study involved 234 women (58 women with no blastocysts in the first IVM cycle and 158 women who underwent the first IVF cycle). Cumulative live birth rate at 12 months after oocyte retrieval and OHSS of a standard controlled ovarian stimulation (COS) IVF cycle were compared between 58 women in an IVF cycle following a failed IVM cycle and 158 women who underwent the first IVF cycle. Results: No significant differences were found in the cumulative live birth rate (CLBR), ongoing pregnancy rate, or clinical pregnancy rate at 12 months after oocyte retrieval between the two groups (56.9% vs. 58.9%, p = 0.795; 58.6% vs. 60.8%, p = 0.776; and 84.5% vs. 76.0%, p = 0.178). The incidence of moderate-to-severe OHSS was not significantly different between the groups (6.9% vs. 5.7%, p = 0.742). Additionally, there were no significant differences in the total gonadotropin dose, stimulation duration, number of retrieved oocytes, number of retrieved mature oocytes, or fertilization rates. Conclusions: Even if the first IVM attempt failed in subfertile women with PCOS, comparable cumulative live birth rates were observed in the subsequent IVF cycle. IVM treatment does not adversely affect the subsequent IVF cycle.
- 4 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5761
Open AccessOutcomes of the Next In Vitro Fertilization Cycle in Women with Polycystic Ovary Syndrome after a Failed In Vitro Maturation Attempt
Background: In vitro maturation (IVM) is indicated in women with polycystic ovary syndrome (PCOS) who have a very good ovarian response during in vitro fertilization (IVF) and are therefore at high risk of ovarian hyperstimulation syndrome (OHSS). According to the latest practice committee document, IVM could be a major advance in assisted reproductive technology (ART) procedures (reduced cost and simplified treatment); nevertheless, retrospective studies of IVM versus IVF still demonstrate lower chances of a live birth with IVM. Could IVM prove to be an optimal first-line treatment approach? And limited information is available concerning the success of the subsequent IVF cycle after the failure of an IVM cycle. Does IVM treatment adversely affect the subsequent IVF cycle, and is this worth considering before performing the IVF cycle for women with PCOS? Methods: This prospective nested case–control study at the Peking University Reproductive Medicine center in China was performed between March 2018 and September 2020. Women aged 20–38 years with PCOS and infertility and who were scheduled for their first IVF attempt were eligible. A total of 351 women were randomly allocated to receive one cycle of unstimulated natural IVM (n = 175) or one cycle of standard IVF with a flexible GnRH antagonist protocol followed by hCG as an ovulation trigger (n = 176). This study involved 234 women (58 women with no blastocysts in the first IVM cycle and 158 women who underwent the first IVF cycle). Cumulative live birth rate at 12 months after oocyte retrieval and OHSS of a standard controlled ovarian stimulation (COS) IVF cycle were compared between 58 women in an IVF cycle following a failed IVM cycle and 158 women who underwent the first IVF cycle. Results: No significant differences were found in the cumulative live birth rate (CLBR), ongoing pregnancy rate, or clinical pregnancy rate at 12 months after oocyte retrieval between the two groups (56.9% vs. 58.9%, p = 0.795; 58.6% vs. 60.8%, p = 0.776; and 84.5% vs. 76.0%, p = 0.178). The incidence of moderate-to-severe OHSS was not significantly different between the groups (6.9% vs. 5.7%, p = 0.742). Additionally, there were no significant differences in the total gonadotropin dose, stimulation duration, number of retrieved oocytes, number of retrieved mature oocytes, or fertilization rates. Conclusions: Even if the first IVM attempt failed in subfertile women with PCOS, comparable cumulative live birth rates were observed in the subsequent IVF cycle. IVM treatment does not adversely affect the subsequent IVF cycle.
- Open Access
- 2 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1978
Effectiveness, Flexibility and Safety of Switching IVF to IVM as a Rescue Strategy in Unexpected Poor Ovarian Response for PCOS Infertility Patients
Background: According to the latest practice committee document, in vitro maturation (IVM) is a simple and safe procedure, especially in patients with polycystic ovary syndrome (PCOS). Does switching from in vitro fertilization (IVF) to IVM (IVF/M) help as a rescue infertility treatment for PCOS patients with an unexpected poor ovarian response (UPOR) tendency? Methods: This retrospective cohort study included 531 women with PCOS who had undergone 588 natural IVM cycles or had switched to IVF/M cycles from 2008 to 2017. Natural IVM was performed in 377 cycles, and switching IVF/M was performed in 211 cycles. The primary outcome measure was the cumulative live birth rates (cLBRs), and the secondary outcomes included laboratory and clinical outcomes, maternal safety, and obstetric and perinatal complications. Results: No significant difference was found in the cLBRs between the natural IVM and switching IVF/M groups (23.6% vs. 17.4%, p = 0.05). Meanwhile, the natural IVM group had a higher cumulative clinical pregnancy rate (36.0% vs. 26.0%, p = 0.01), and a decrease in the number of oocytes was obtained in the switching IVF/M group (13.5 vs. 12.0, p < 0.01). The number of good quality embryos in the natural IVM group was 2.2 ± 2.5, and 2.1 ± 2.3 (p = 0.64) in the switching IVF/M group. No statistically significant differences were observed in the number of 2 pronuclear (2PN) and available embryos. Ovarian hyperstimulation syndrome (OHSS) did not occur in the switching IVF/M and natural IVM groups, indicating a highly favorable outcome. Conclusion: In PCOS infertile women with UPOR, timely switching IVF/M is a viable option that markedly reduces the canceled cycle, results in reasonable oocyte retrieval, and leads to live births.
- 2 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1978
Open AccessEffectiveness, Flexibility and Safety of Switching IVF to IVM as a Rescue Strategy in Unexpected Poor Ovarian Response for PCOS Infertility Patients
Background: According to the latest practice committee document, in vitro maturation (IVM) is a simple and safe procedure, especially in patients with polycystic ovary syndrome (PCOS). Does switching from in vitro fertilization (IVF) to IVM (IVF/M) help as a rescue infertility treatment for PCOS patients with an unexpected poor ovarian response (UPOR) tendency? Methods: This retrospective cohort study included 531 women with PCOS who had undergone 588 natural IVM cycles or had switched to IVF/M cycles from 2008 to 2017. Natural IVM was performed in 377 cycles, and switching IVF/M was performed in 211 cycles. The primary outcome measure was the cumulative live birth rates (cLBRs), and the secondary outcomes included laboratory and clinical outcomes, maternal safety, and obstetric and perinatal complications. Results: No significant difference was found in the cLBRs between the natural IVM and switching IVF/M groups (23.6% vs. 17.4%, p = 0.05). Meanwhile, the natural IVM group had a higher cumulative clinical pregnancy rate (36.0% vs. 26.0%, p = 0.01), and a decrease in the number of oocytes was obtained in the switching IVF/M group (13.5 vs. 12.0, p < 0.01). The number of good quality embryos in the natural IVM group was 2.2 ± 2.5, and 2.1 ± 2.3 (p = 0.64) in the switching IVF/M group. No statistically significant differences were observed in the number of 2 pronuclear (2PN) and available embryos. Ovarian hyperstimulation syndrome (OHSS) did not occur in the switching IVF/M and natural IVM groups, indicating a highly favorable outcome. Conclusion: In PCOS infertile women with UPOR, timely switching IVF/M is a viable option that markedly reduces the canceled cycle, results in reasonable oocyte retrieval, and leads to live births.
- Open Access
- 5 January 2023
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 9, 1076889
The influence of timing of oocytes retrieval and embryo transfer on the IVF-ET outcomes in patients having bilateral salpingectomy due to bilateral hydrosalpinx
Objective: The objective of the study was to investigate whether the sequence of oocyte retrieval and salpingectomy for hydrosalpinx affects pregnancy outcomes of in vitro fertilization and embryo transfer (IVF-ET) patients.Study Design: There were 1,610 bilateral hydrosalpinx patients who underwent laparoscopy salpingectomy and IVF-ET/intracytoplasmic sperm injection (ICSI) from January 2009 to December 2018. They were divided into two groups: oocyte retrieval first group: 235 accepted oocyte retrieval before salpingectomy; operation first group: 1,375 accepted oocyte retrieval after salpingectomy. The basic information and pregnancy outcomes of the two groups were compared. The pregnancy outcomes and influencing factors were analyzed among patients at different starting times of frozen-thawed embryo transfer (FET) or oocyte retrieval after the salpingectomy.Results: Patients in the oocyte retrieval first group had higher levels of basal follicle stimulating hormone and lower anti-Mullerian hormone levels (P < 0.05). There were no cases of pelvic infection or oocyte and embryo contamination after oocyte retrieval in the oocyte retrieval first group. In the frozen cycle, the clinical pregnancy and miscarriage rates of the oocyte retrieval first group were lower than those in the operation first group (P < 0.05), while the live birth rate was not significantly different (P > 0.05). The live birth rates of patients ≥35 years old in the operation first group and the oocyte retrieval first group were not significantly different (29.3% vs. 23.3%, P = 0.240). After adjusting for age and antral follicle count (AFC), oocyte retrieval 4–6 and 7–12 months after the operation had higher accumulated pregnancy rates [OR 1.439 (1.045–1.982), P = 0.026; OR 1.509 (1.055–2.158), P = 0.024] and higher accumulated live birth rates [OR 1.419 (1.018–1.977), P = 0.039; OR 1.544 (1.068–2.230), P = 0.021]. No significant difference was observed in the pregnancy outcomes of frozen embryo transfer at different times after salpingectomy (P > 0.05).Conclusion: No contamination of the embryo or infection was observed in patients who underwent oocyte retrieval before the operation. The interval between the operation and frozen embryo transfer did not affect the pregnancy outcomes. After adjusting for age and AFC, patients who underwent oocyte retrieval 4–6 and 7–12 months after the operation had higher accumulated pregnancy rates and live birth rates.
- 5 January 2023
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 9, 1076889
Open AccessThe influence of timing of oocytes retrieval and embryo transfer on the IVF-ET outcomes in patients having bilateral salpingectomy due to bilateral hydrosalpinx
Objective: The objective of the study was to investigate whether the sequence of oocyte retrieval and salpingectomy for hydrosalpinx affects pregnancy outcomes of in vitro fertilization and embryo transfer (IVF-ET) patients.Study Design: There were 1,610 bilateral hydrosalpinx patients who underwent laparoscopy salpingectomy and IVF-ET/intracytoplasmic sperm injection (ICSI) from January 2009 to December 2018. They were divided into two groups: oocyte retrieval first group: 235 accepted oocyte retrieval before salpingectomy; operation first group: 1,375 accepted oocyte retrieval after salpingectomy. The basic information and pregnancy outcomes of the two groups were compared. The pregnancy outcomes and influencing factors were analyzed among patients at different starting times of frozen-thawed embryo transfer (FET) or oocyte retrieval after the salpingectomy.Results: Patients in the oocyte retrieval first group had higher levels of basal follicle stimulating hormone and lower anti-Mullerian hormone levels (P < 0.05). There were no cases of pelvic infection or oocyte and embryo contamination after oocyte retrieval in the oocyte retrieval first group. In the frozen cycle, the clinical pregnancy and miscarriage rates of the oocyte retrieval first group were lower than those in the operation first group (P < 0.05), while the live birth rate was not significantly different (P > 0.05). The live birth rates of patients ≥35 years old in the operation first group and the oocyte retrieval first group were not significantly different (29.3% vs. 23.3%, P = 0.240). After adjusting for age and antral follicle count (AFC), oocyte retrieval 4–6 and 7–12 months after the operation had higher accumulated pregnancy rates [OR 1.439 (1.045–1.982), P = 0.026; OR 1.509 (1.055–2.158), P = 0.024] and higher accumulated live birth rates [OR 1.419 (1.018–1.977), P = 0.039; OR 1.544 (1.068–2.230), P = 0.021]. No significant difference was observed in the pregnancy outcomes of frozen embryo transfer at different times after salpingectomy (P > 0.05).Conclusion: No contamination of the embryo or infection was observed in patients who underwent oocyte retrieval before the operation. The interval between the operation and frozen embryo transfer did not affect the pregnancy outcomes. After adjusting for age and AFC, patients who underwent oocyte retrieval 4–6 and 7–12 months after the operation had higher accumulated pregnancy rates and live birth rates.